Format

Send to

Choose Destination
See comment in PubMed Commons below
Drugs R D. 2010;10(1):55-65. doi: 10.2165/11538300-000000000-00000.

Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B.

[No authors listed]

Abstract

Belimumab is a fully human monoclonal antibody for the treatment of autoimmune disorders that is being developed by Human Genome Sciences and GlaxoSmithKline. Two pivotal phase III trials in systemic lupus erythematosus have been concluded with the primary endpoints being met in both studies. A phase II trial in rheumatoid arthritis has also been completed, with positive results. Marketing authorization submissions are being prepared in the major markets worldwide. This review discusses the development history and scientific profile of belimumab.

PMID:
20509716
PMCID:
PMC3585980
DOI:
10.2165/11538300-000000000-00000
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center